Inhibition of Mutated, Activated BRAF in Metastatic MelanomaKeith T. Flaherty, Paul B. Chapman, Peter J. O’Dwyer et al.|New England Journal of Medicine|2010Cited by 3.5k
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanomaGideon Bollag, K. B. Nolop, Peter Hirth et al.|Nature|2010Cited by 1.8k
Pharmacokinetically Guided Phase 1 Trial of the IGF-1 Receptor Antagonist RG1507 in Children with Recurrent or Refractory Solid TumorsR. Bagatell, Lia Gore, Cynthia E. Herzog et al.|Clinical Cancer Research|2010Cited by 48